Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

41.15 -1.51 (-3.54%)
Streaming Delayed Price Updated: 3:05 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 Next >
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Appoints John Furey to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Pricing of $750 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.